NCT05272384 2026-03-18Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaNational Cancer Institute (NCI)Phase 1 Recruiting32 enrolled
NCT03907488 2025-12-04Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting994 enrolled 11 charts